Objective To evaluate the safety and clinical efficacy of DC-CIK cell combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Methods A total of 112 patients with NSCLC were randomly divided into observation group (n=56) and control group (n=56), the observation group was treated with DC-CIK immunotherapy combined with chemotherapy, and the control group was treated with chemotherapy only, then the efficacy and safety were compared between the two groups.Results The response rate of the observation group and the control group were 60.7% and 48.9%, respectively, and there was no significantly difference(P>0.05), and the disease control rate of the observation group was 89.3%, which was higher than 73.2% in the control group(P<0.05).The KPS score in the observation group after treatment was significantly higher than that in the control group (P<0.05).Compared with the control group, the observation group had less toxicity reaction, and longer middle survival time (P<0.05).Conclusion DC-CIK cell combined with chemotherapy can effectively increase the disease control rate, extend the survival time, and improve the quality of life in patients with NSCLC, so it is worthy of promotion.%目的 探讨DC-CIK联合化疗治疗晚期非小细胞肺癌的疗效及安全性.方法 112例晚期非小细胞肺癌患者随机分为实验组(n=56)和对照组(n=56),实验组给予DC-CIK细胞联合化疗治疗,对照组仅给予化疗治疗,比较2组的疗效及安全性.结果 2组有效率分别为60.7%和48.9%, 差异无统计学意义(P>0.05);实验组疾病控制率为89.3%, 显著高于对照组的73.2%(P<0.05);治疗后实验组KPS评分提高率显著高于对照组(P<0.05);实验组患者的毒副反应显著轻于对照组,中位生存期显著长于对照组 (P<0.05).结论 DC-CIK细胞与化疗联合用于晚期非小细胞肺癌的治疗,能够有效提高疾病控制率,延长患者生存期,改善患者生存质量.
展开▼
